Also known as: SEC
XRP price flashed a gravestone doji after a $1.35-$1.65 rally, signaling potential reversal. Analysts target $0.80-$0.91 based on the 200-week EMA loss and Gaussian Channel, while key resistance sits at $2.10-$2.14.
Federal courts are weighing whether the April 2026 marijuana rescheduling order was lawful. MMJ argues the Attorney General skipped required rulemaking; DEA testimony flagged omitted diversion analysis. A stay motion is pending.
AI drug discovery is moving from hype to proof in 2026, with multi-billion-dollar partnerships, new joint initiatives, and major investments accelerating AI-native biotech pipelines and data-driven deals.
XRP hovered near $1.09 on July 25 despite Ripple's EU MiCA approval and Evernorth's $1 billion XRP treasury plan. Technical resistance and slowing ETF inflows capped gains; RLUSD supply reached $1.51B.
New investment models and digital twin technologies are bridging gaps in rare disease drug development, where traditional funding and trial designs fall short. Patient-led funding and family offices provide capital, while regulators accept digital evidence to accelerate therapies for the more than 7,000 rare diseases with few approved treatments.
MassBio's Align Summit 2026 returns October 15 in Boston with 50+ startups and AI drug discovery tracks. The SITC EU summit adds a pre-clinical models panel, and UCLA's Cell-Cell Symposium 2026 tackles single-cell spatial data challenges.
The SEC is pursuing insider trading cases involving inadvertent tips of MNPI, including a cousin who traded on confidential FDA approval news and a family member with workspace access during an acquisition.
AbbVie has received a "Moderate Buy" consensus rating from analysts with an average price target of $253.15. The company reported strong quarterly earnings of $2.71 EPS and $16.62 billion revenue, beating estimates. Recent clinical progress includes positive Phase 1 results for an obesity drug candidate showing 7.8-9.8% weight loss.
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
